Preparation and characterization of carrier-free dry powder inhalers containing nanosized active ingredient by Party, Petra & Ambrus, Rita
III. Symposium of Young Researchers on Pharmaceutical 
Technology, Biotechnology and Regulatory Science 






Preparation and characterization of carrier-free dry 
powder inhalers containing nanosized active ingredient 
Petra Party, Rita Ambrus 
Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, 
University of Szeged, Szeged, Hungary 
 
Pulmonary drug delivery provides rapid onset of action, large surface area for absorption and 
limited drug degradation. With the development of innovative dry powder inhalers, we could 
improve the therapeutic effect. The non-steroidal anti-inflammatory meloxicam was the 
active ingredient, which could be useful for the treatment of lung cancer, cystic fibrosis and 
chronic obstructive pulmonary disease. 
Our aim was to produce dry powder inhalers containing nanonized meloxicam. We targeted 
different regions of the lung with micrometric particles prepared by Mini Spray-Dryer and 
nanometric samples produced by Nano Spray-Dryer.  
We used a two-step preparation method. The nanosuspension was prepared with wet milling, 
using meloxicam and polyvinyl alcohol. The powders were obtained with spray-drying of the 
nanosuspension and using leucine. We measured the following properties: particle size (laser 
diffraction, DLS), morphology (SEM), true density, structure (XRPD), thermoanalytical 
properties (DSC), in vitro dissolution, in vitro absorption, in vitro lung deposition (Andersen 
Cascade Impactor). 
We worked out a powder preparation method, using wet milling and spray drying. We 
managed to nanonize the active ingredient and prepare 3-4 µm particles by Mini Spray-Dryer 
and 500-800 nm particles by Nano Spray-Dryer. The particles were spherical with low density. 
Thanks to the improved surface area and amorphization, released and absorbed amount of 
meloxicam increased. The in vitro aerodynamic measurements proved that with the 
microsized particles we targeted the bronchioles and with the nanosized we reached the 
alveoli. 
The samples are suitable for pulmonary delivery; therefore, our products could treat different 
respiratory diseases in the future. 
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